Navigation Links
Brazil's Rheumatoid Arthritis Drug Market Will Grow $115 Million by 2013
Date:7/20/2009

WALTHAM, Mass., July 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that the rheumatoid arthritis drug market in Brazil will grow from $200 million in 2008 to more than $315 million in 2013. The 2008 market leaders were the tumor necrosis factor-alpha (TNF-alpha) inhibitors Abbott's Humira and Schering-Plough's Remicade which recorded sales of $50 million and $43 million, respectively, despite a combined patient share of two percent. Wyeth's Enbrel, the third marketed agent from this class, recorded fewer sales because of its inconvenient dosing frequency and its availability only in a lyophilized form.

The new Emerging Markets report entitled Rheumatoid Arthritis in Brazil also finds that survey results of Brazilian rheumatologists show regional differences in their preferences for agents within key drug classes for rheumatoid arthritis. While Enbrel emerges as the patient share leader among biologics in Rio de Janeiro, rheumatologists from Sao Paulo and Belo Horizonte prefer Humira and Remicade, respectively.

"Competition among TNF-alpha inhibitors is influenced by a drug's clinical profile, order of market entry, ease of access in the public sector, patients' socioeconomic status, ease of administration and marketing campaigns," stated Irene Koulinska, Sc.D., M.D.

The new report is part of an expansion of the Emerging Markets report series to cover Brazil. The series contains primary research of physicians and epidemiology study in key pharmaceutical markets of Brazil--Rio de Janeiro, Sao Paulo and Belo Horizonte.

About Emerging Markets Reports

Decision Resources is the FIRST and ONLY company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians' practices.

About Decision Resources

Decision Resources (www.DecisionResources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

For more information, contact:

    Gisselle Morales                             Elizabeth Marshall
    Decision Resources                           Decision Resources, Inc.
    781-296-2691                                 781-296-2563
    gmorales@dresources.com                      emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Chinas Rheumatoid Arthritis Drug Market Will More than Double by 2013
2. New Drug Promising Against Rheumatoid Arthritis
3. Over half of people with rheumatoid arthritis have periodontitis
4. Exercise improves functional and psycological ability and reduces steroid need in rheumatoid arthritis
5. Rheumatoid arthritis is associated with poor sleep in women
6. Rheumatoid Arthritis Drug Might Fight Swine Flu
7. Treating gum disease helps rheumatoid arthritis sufferers
8. For the Treatment of Rheumatoid Arthritis, Market Share for TNF-alpha Inhibitors Will Decrease Through 2018
9. Nektar Announces UCBs Cimzia(R) Approved by U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
10. UCBs CIMZIA(R) (certolizumab pegol) Approved by the U.S. FDA for Adult Patients Suffering From Moderate to Severe Rheumatoid Arthritis
11. SIMPONI(TM) (golimumab) Receives FDA Approval as First Once-Monthly Anti-TNF for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... ... Transformation Solutions, LLC to help enterprises move workloads to the cloud. Cirracore ... connect to their cloud without traversing the Internet. Transformation Solutions (TSL Partners) ...
(Date:2/9/2016)... ... , ... Establishment Labs, a global breast implant and medical technology company, is ... Directors. , “We are honored to welcome David to our Board of ... Chacon Quiros, CEO of Establishment Labs. "David’s knowledge and experience will be invaluable to ...
(Date:2/9/2016)... ... February 09, 2016 , ... The Bon-Ton Stores, ... Younkers department stores, announced it has raised $176,000 to benefit the Breast Cancer ... Cancer Center at the University of Iowa, The Lynn Sage Cancer Research Foundation, ...
(Date:2/9/2016)... ... ... METTLER TOLEDO has published a new guide entitled “Essential ... the techniques they use so they can more easily spot potential error sources ... to create a leaner overall lab experience. , The new guide offers ...
(Date:2/9/2016)... ... February 09, 2016 , ... United Methodist Communications ... of Prevention,” an animated video designed to prevent the next widespread ... the video are being distributed throughout Togo, Liberia, Sierra Leone, Nigeria, Côte d’Ivoire ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)... Feb. 9, 2016  Axovant Sciences Ltd. (NYSE: ... the treatment of dementia, today announced further details ... behavioral and functional aspects of Lewy body dementia, ... the U.S. Two out of the three studies ... to start later this quarter. In addition, the ...
(Date:2/9/2016)... The new report "Global Diagnostic Ultrasound Devices Market Assessment ... reveals that global diagnostic ultrasound devices market was valued at US$ ... million by 2019 at a CAGR of 6.8% from 2015 to ... has been analyzed for six geographies of North America ... , Latin America , Middle-East ...
(Date:2/9/2016)... 9, 2016 The new report "Global Blood Monitoring & Cardiac Monitoring ... & Consulting group reveals that global market for blood monitoring & ... and expected to grow to US$ 24,830.1 million by 2019 at ... North America , Europe , ... Middle-East and Africa . The three ...
Breaking Medicine Technology: